Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614467 · ClinicalTrials.gov registry record · Phase 2
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
A Phase 2 study, sponsored by Lisata Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT04614467 is a Phase 2 study that was terminated before completion, run by Lisata Therapeutics. The registered enrollment target is 34 participants.
The verdict
NCT04614467, a Phase 2 study, was terminated before completion, sponsored by Lisata Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single administration of CLBS16 or placebo.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CLBS16
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2022-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04614467
The ClinicalTrials.gov registry entry for NCT04614467 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lisata Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04614467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04614467 about?
NCT04614467 is a clinical study titled "A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction". This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single administration of CLBS16 or placebo.
What is the current status of trial NCT04614467?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2020-10-29. Estimated completion is 2022-09-28.
What interventions are being tested in trial NCT04614467?
The interventions under investigation include: Placebo (BIOLOGICAL), CLBS16 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04614467?
This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.